Cadrenal Therapeutics, Inc.

Frunexian has been successfully tested in two Phase 1 clinical trials in healthy volunteers. The results showed that the drug was well tolerated at doses up to 2.25 mg/kg/h and there were no reports of serious adverse events. Steady-state plasma levels of the drug were rapidly achieved, and importantly the drug was quickly cleared following cessation of dosing, an important factor for use in the acute care setting. The company has additional work to perform regarding the manufacturing of frunexian before initiating the clinical trial plan, which may initially focus on complex cardiac surgery. 

Clinical Trial Planned in ESKD w/ Atrial Fibrilation Transitioning to Dialysis 

In August 2025, Cadrenal announced plans for a clinical trial for tecarfarin in patients with end-stage kidney disease (ESKD) that are transitioning to dialysis. We anticipate enrollment initiating in the first quarter of 2026 and topline data could be available approximately one year following the start of the trial.

Patients with chronic kidney disease (CKD) have a high risk for cardiovascular events: approximately half of CKD stage 4 and 5 (ESKD) have cardiovascular disease (CVD) (Stevens et al., 2007), and cardiovascular Page 2                                                            scr.zacks.com Zacks Investment Research                                          mortality is one of the leading causes of death in patients with advanced CKD (Webster et al., 2016). There is conflicting data available as to whether current anticoagulation therapy options (both warfarin and DOACs) are effective at preventing CV events in these patients. The RENAL-AF trial compared apixaban to warfarin in dialysis patients with atrial fibrillation (AF), however the study had inadequate power to draw any conclusion regarding rates of major or clinically relevant nonmajor bleeding, although it was noted that bleeding events were much more common than stroke events in that population (Pokorney et al., 2022). Pooled observation data suggest that DOACs may have similar stroke prevention and potentially lower major bleeding vs. warfarin, however the evidence is low-quality and heterogeneous (Shen et al., 2023). The bottom line is that a new treatment option is necessary for dialysis patients with ESKD. Tecarfarin activity is not affected in ESKD patients, thus making it a suitable compound to test as an anticoagulant therapy in that population.

Financial Update

On August 11, 2025, Cadrenal announced financial results for the second quarter of 2025. As expected, the company did not record any revenues for the three months ending June 30, 2025. R&D expenses in the second quarter of 2025 were $1.1 million compared to $1.3 million in the second quarter of 2024. The decrease was primarily due to decreased consulting expenses partially offset by an increase in CMC costs. G&A expenses were $2.7 million in the second quarter of 2025 compared to $1.2 million in the second quarter of 2024. The increase was primarily due to increased public company expenses and non-cash stock-based compensation As of June 30, 2025, Cadrenal had approximately $5.6 million in cash and cash equivalents While the company has sufficient capital to fund operations for the next 12 months, it will need to raise additional capital to conduct the planned clinical trials for tecarfarin and frunexian. The company currently has approximately 2.0 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 3.1 million. 

Conclusion

Cadrenal has now enhanced its pipeline with the acquisition of frunexian and the other Factor XIa inhibitors and we look forward to additional information regarding their development. The shift to focusing on ESKD patients for tecarfarin is important as there is a significant need for effective anticoagulant therapy for those patients and we believe positive results could also serve to de-risk the development of tecarfarin in other indications such as in LVAD patients. Before incorporating frunexian into our model we will wait and see what development path the company decides to pursue with it, thus our valuation remains at $30 per share.

sdfdsfds

PROJECTED FINANCIALS

Image Source: Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research